Summary & Overview
CPT 0223U: QIAstat–Dx Respiratory SARS–CoV–2 Multiplex PCR Panel
CPT code 0223U denotes a Proprietary Laboratory Analyses (PLA) test for the QIAstat–Dx® Respiratory SARS CoV–2 Panel, an automated multiplex PCR assay run on nasopharyngeal specimens to detect common viral and bacterial respiratory pathogens including SARS–CoV–2. As a PLA code, 0223U uniquely identifies a single manufacturer's test, which supports lab-level tracking, reimbursement specificity, and clinical use monitoring nationwide. National relevance stems from continued demand for multiplex respiratory diagnostics during seasonal respiratory illness and ongoing SARS–CoV–2 surveillance.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise summary of coverage and coding context for those payers, benchmarking guidance where available, and the clinical and billing context necessary to understand how this PLA code fits into molecular diagnostic workflows. The publication outlines the service type, typical site of service, and payer coverage landscape; identifies common modifiers and coding mechanics; and highlights implications for laboratory billing, claims submission, and payer adjudication. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0223U is a Proprietary Laboratory Analyses (PLA) code for the QIAstat–Dx® Respiratory SARS CoV–2 Panel from QIAGEN Sciences. This test is an automated polymerase chain reaction (PCR) assay performed on a nasopharyngeal specimen that detects the most common viral and bacterial respiratory pathogens, including SARS–CoV–2.
Service Type: Automated PCR-based multiplex respiratory pathogen panel
Typical Site of Service: Clinical laboratory or hospital laboratory performing high-throughput molecular diagnostics
Clinical & Coding Specifications
Clinical Context
A symptomatic adult or pediatric patient presents to an outpatient clinic, urgent care, emergency department, or hospital with acute respiratory symptoms such as fever, cough, sore throat, nasal congestion, shortness of breath, or myalgias. The clinician suspects a viral or atypical bacterial respiratory infection and orders multiplex molecular testing. A nasopharyngeal swab (or other validated upper respiratory specimen) is collected and sent to the laboratory. The laboratory performs the proprietary automated PCR assay QIAstat–Dx® Respiratory SARS Co–V–2 Panel and reports results for the most common viral and bacterial respiratory pathogens, including SARS–CoV–2. Results guide infection control decisions, antiviral or antibacterial therapy considerations, patient triage, and public health reporting. Typical workflow steps: specimen collection with appropriate PPE, specimen transport to the laboratory, accessioning, running the QIAstat–Dx assay per manufacturer instructions, verification of internal controls, result interpretation, and reporting into the electronic medical record and to public health if required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default — no modifier | Use when no other modifier applies and the full procedural service is reported |
22 | Increased procedural services | Use when substantially greater lab resources or complexity were required beyond usual test performance and documentation supports unusual effort
26 | Professional component | Use when billing only the professional component (interpretation) separate from the technical component
52 | Reduced services | Use when the test was partially reduced or not completed as originally intended
53 | Discontinued procedure | Use when testing was started but stopped due to patient condition or other clinical reasons
62 | Two surgeons / two qualified providers | Generally not applicable to lab tests but may apply when two qualified providers share responsibility for professional interpretation
78 | Unplanned return to the operating/procedure room | Not typically used for this lab test; reserved for surgical procedures
80 | Assistant surgeon | Not applicable to laboratory testing; included for completeness in modifier lists
AS | Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery | Not applicable for this lab test
QW | CLIA-waived test | Use when the test performed is CLIA-waived; if QIAstat–Dx panel is performed under waived status and payer accepts modifier
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207Q00000X | Infectious Disease Specialist | Oversees complex diagnostic interpretation and patient management decisions |
207P00000X | Pathology | Clinical pathologists direct laboratory testing and result validation
207L00000X | Medical Laboratory Technologist | Performs and validates the molecular assay in the lab
363A00000X | Emergency Medicine Physician | Orders testing for acutely ill patients in ED settings
207LP2900X | Clinical Microbiology | Specialty focus on respiratory pathogen testing and stewardship
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
J06.9 | Acute upper respiratory infection, unspecified | Common presenting diagnosis for patients with viral respiratory symptoms who receive multiplex testing |
J22 | Unspecified acute lower respiratory infection | Used when lower respiratory tract infection is suspected and broad pathogen testing is indicated
J12.89 | Other viral pneumonia | Relevant when viral pneumonia is suspected and multiplex PCR can identify viral etiologies including SARS-CoV-2
J18.9 | Pneumonia, unspecified organism | Broad pneumonia diagnosis where identifying causative pathogens guides therapy
R05 | Cough | Symptom code frequently accompanying testing for respiratory pathogens
R50.9 | Fever, unspecified | Non-specific symptom prompting evaluation for infectious respiratory causes
Z20.828 | Contact with and (suspected) exposure to other viral communicable diseases | Used when exposure history raises suspicion and testing is performed for surveillance or diagnostic clarification
U07.1 | COVID-19 | Specific diagnosis used when SARS-CoV-2 infection is confirmed or suspected and testing is performed
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
0223U | QIAstat–Dx® Respiratory SARS Co–V–2 Panel — automated PCR on nasopharyngeal specimen for multiple viral and bacterial respiratory pathogens including SARS–CoV–2 | Primary PLA code reported for this proprietary multiplex molecular assay |
87426 | Infectious agent antigen detection by immunoassay technique, multiple-step method; respiratory virus (e.g., influenza), each | Common point-of-care or lab antigen tests that may be performed prior to or instead of multiplex PCR in some workflows
87635 | Infectious agent detection by nucleic acid (DNA or RNA); SARS-CoV-2, amplified probe technique | SARS-CoV-2–specific NAAT that may be ordered alone when targeted testing for COVID-19 is desired
87804 | Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; respiratory panel, non-proprietary | Alternative molecular respiratory panel codes when a non-PLA multiplex assay is used
99000 | Handling and/or setup; each specimen (clinical lab) | Ancillary billing code sometimes used for specimen handling or special processing, depending on payer policy